iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

NASHUA, N.H., Nov. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will attend the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19, 2024 at the Sheraton New York Times Square Hotel in New York City, New York. Management will be available for one-on-one meetings throughout the day. To request a meeting with iCAD, investors should contact their Craig-Hallum representative.

iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference

Nashua, New Hampshire--(Newsfile Corp. - October 16, 2024) - iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October 29-30, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation at 10:30 a.m.

iCAD to Participate in the LD Micro Main Event XVII

NASHUA, N.H. and PARIS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France. At JFR, iCAD will premier ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company's advanced AI solutions to healthcare providers worldwide.

iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024

iCAD, Inc. (NASDAQ:ICAD ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Capital Yale Jen - Laidlaw & Company Operator Good day and welcome to the iCAD Incorporated Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

iCAD, Inc. (ICAD) Q2 2024 Earnings Call Transcript

NASHUA, N.H., Aug. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months ended June 30, 2024.

iCAD Reports Financial Results for Second Quarter Ended June 30, 2024

Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion Windsong Radiology to Champion First Wave of ProFound AI Breast Health Suite Expansion

iCAD and Windsong Radiology Announce Strategic Commercial Agreement to Implement AI-Powered Mammography

Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions

iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event.

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

Innodata

Mitek Systems

It's certainly a very good time to be in the AI business. After all, the technology has been getting huge amounts of positive publicity since December 2022, and it's being viewed as a powerful, helpful tool for humans.

3 Top Small-Cap Growth Opportunities in the AI Era

iCAD, Inc. (NASDAQ:ICAD ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Jeremiah Bennett - Vice President, Marketing Dana Brown - President and Chief Executive Officer Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Yale Jen - Laidlaw & Company Operator Good day, ladies and gentlemen, and welcome to the iCAD Incorporated First Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode, and floor will be open for questions and comments following the presentation.

iCAD, Inc. (ICAD) Q1 2024 Earnings Call Transcript

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024.

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024.

UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024.

iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also highlighting its recently announced partnership with Densitas®, a global leader in AI solutions for breast cancer screening, at the Society for Breast Imaging (SBI) annual symposium, April 11-14 in Montreal, Canada. In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman's breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk.

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms

iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detection ProFound Cloud redefines accessibility to critical insights, empowering radiologists in early breast cancer detection

iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale

Broadcom

Iron Mountain

The market is overlooking many stocks that could benefit from the proliferation of AI over the longer term. There are companies using AI to solve real-world problems, and others providing the raw materials that enable the AI boom to progress.

Artificial Intelligence, Real Profits: 3 Stocks to Outsmart the Market

iCAD, Inc. (ICAD) Q4 2023 Earnings Call Transcript

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year Year ending cash balance of $21.7M

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

C3.ai

Schrodinger 

Wall Street has correctly recognized that artificial intelligence (AI) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex questions.

The Hot List: 3 AI Stocks Worth Buying on Weakness

NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, Feb 28 – March 3, 2024. The Company also announced it will highlight a new release for its AI-powered ProFound Detection solution while showcasing its full Breast Health Suite in booth X1 AI-35.

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the Company will release financial results for the fourth quarter and full year 2023 financials after the market close, and host a conference call at 4:30 PM Eastern Time on Tuesday, March 12, 2024.

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Blink Charging

Bionano Genomics

While it's never easy to identify multibagger stocks, this may be one of the best times in decades to “swing for the fences” by buying undervalued growth names that are well-positioned to at least triple over the next few years. Amid excessive worries about interest rates, the Street has pushed down many unprofitable, high-potential companies' stocks to absurdly low levels.

News for iCAD Stock (ICAD)